Molecular targeted therapy of BRAF-mutant colorectal cancer

Over the past two decades, the molecular characterization of metastatic colorectal cancer (mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As a result, it is now known that patients with mCRC harboring BRAF mutations experience a poor prognosis. Although it account...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Med Oncol
Egile Nagusiak: Ducreux, Michel, Chamseddine, Ali, Laurent-Puig, Pierre, Smolenschi, Cristina, Hollebecque, Antoine, Dartigues, Peggy, Samallin, Emmanuelle, Boige, Valérie, Malka, David, Gelli, Maximiliano
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582307/
https://ncbi.nlm.nih.gov/pubmed/31244912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919856494
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak